These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

281 related items for PubMed ID: 6790606

  • 21. An oligosaccharide-tetanus toxoid conjugate vaccine against type III group B Streptococcus.
    Paoletti LC, Kasper DL, Michon F, DiFabio J, Holme K, Jennings HJ, Wessels MR.
    J Biol Chem; 1990 Oct 25; 265(30):18278-83. PubMed ID: 2120228
    [Abstract] [Full Text] [Related]

  • 22. A novel combined Haemophilus influenzae type b-Neisseria meningitidis serogroups C and Y-tetanus-toxoid conjugate vaccine is immunogenic and induces immune memory when co-administered with DTPa-HBV-IPV and conjugate pneumococcal vaccines in infants.
    Nolan T, Lambert S, Roberton D, Marshall H, Richmond P, Streeton C, Poolman J, Boutriau D.
    Vaccine; 2007 Dec 12; 25(51):8487-99. PubMed ID: 17996996
    [Abstract] [Full Text] [Related]

  • 23. Safety and immunogenicity of capsular polysaccharide-tetanus toxoid conjugate vaccines for group B streptococcal types Ia and Ib.
    Baker CJ, Paoletti LC, Wessels MR, Guttormsen HK, Rench MA, Hickman ME, Kasper DL.
    J Infect Dis; 1999 Jan 12; 179(1):142-50. PubMed ID: 9841833
    [Abstract] [Full Text] [Related]

  • 24. Neonatal mouse protection against infection with multiple group B streptococcal (GBS) serotypes by maternal immunization with a tetravalent GBS polysaccharide-tetanus toxoid conjugate vaccine.
    Paoletti LC, Wessels MR, Rodewald AK, Shroff AA, Jennings HJ, Kasper DL.
    Infect Immun; 1994 Aug 12; 62(8):3236-43. PubMed ID: 8039893
    [Abstract] [Full Text] [Related]

  • 25. Vaccine potential of meningococcal group C polysaccharide-tetanus toxoid conjugate.
    Beuvery EC, Miedema F, van Delft RW, Haverkamp J, Tiesjema RH, Nagel J.
    J Infect; 1983 May 12; 6(3):247-55. PubMed ID: 6411824
    [Abstract] [Full Text] [Related]

  • 26. Preparation and characterization of an immunogenic meningococcal group A conjugate vaccine for use in Africa.
    Lee CH, Kuo WC, Beri S, Kapre S, Joshi JS, Bouveret N, LaForce FM, Frasch CE.
    Vaccine; 2009 Jan 29; 27(5):726-32. PubMed ID: 19063929
    [Abstract] [Full Text] [Related]

  • 27. Induction of cross-reactive antibodies by immunization of healthy adults with types Ia and Ib group B streptococcal polysaccharide-tetanus toxoid conjugate vaccines.
    Brigtsen AK, Kasper DL, Baker CJ, Jennings HJ, Guttormsen HK.
    J Infect Dis; 2002 May 01; 185(9):1277-84. PubMed ID: 12001045
    [Abstract] [Full Text] [Related]

  • 28. Preparation, characterization, and immunogenicity of meningococcal immunotype L2 and L3,7,9 phosphoethanolamine group-containing oligosaccharide-protein conjugates.
    Verheul AF, Braat AK, Leenhouts JM, Hoogerhout P, Poolman JT, Snippe H, Verhoef J.
    Infect Immun; 1991 Mar 01; 59(3):843-51. PubMed ID: 1900063
    [Abstract] [Full Text] [Related]

  • 29.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 30.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 31.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 32. Antibody responses to meningococcal (groups A, C, Y and W135) polysaccharide diphtheria toxoid conjugate vaccine in children who previously received meningococcal C conjugate vaccine.
    El Bashir H, Heath PT, Papa T, Ruggeberg JU, Johnson N, Sinha R, Balfour G, Booy R.
    Vaccine; 2006 Mar 24; 24(14):2544-9. PubMed ID: 16417952
    [Abstract] [Full Text] [Related]

  • 33. Candidacy of LPS-based glycoconjugates to prevent invasive meningococcal disease: developmental chemistry and investigation of immunological responses following immunization of mice and rabbits.
    Cox AD, Zou W, Gidney MA, Lacelle S, Plested JS, Makepeace K, Wright JC, Coull PA, Moxon ER, Richards JC.
    Vaccine; 2005 Oct 17; 23(43):5045-54. PubMed ID: 16046037
    [Abstract] [Full Text] [Related]

  • 34.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 35. Salmonella typhi O-polysaccharide--tetanus toxoid conjugated vaccine.
    Saxena M, Di Fabio JL.
    Vaccine; 1994 Aug 17; 12(10):879-84. PubMed ID: 7526567
    [Abstract] [Full Text] [Related]

  • 36. Structural correlates of carrier protein recognition in tetanus toxoid-conjugated bacterial polysaccharide vaccines.
    Lockyer K, Gao F, Derrick JP, Bolgiano B.
    Vaccine; 2015 Mar 10; 33(11):1345-52. PubMed ID: 25640334
    [Abstract] [Full Text] [Related]

  • 37.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 38. Group B Streptococcus type II polysaccharide-tetanus toxoid conjugate vaccine.
    Paoletti LC, Wessels MR, Michon F, DiFabio J, Jennings HJ, Kasper DL.
    Infect Immun; 1992 Oct 10; 60(10):4009-14. PubMed ID: 1398913
    [Abstract] [Full Text] [Related]

  • 39. Immunochemistry of Salmonella O-antigens: preparation of an octasaccharide-bovine serum albumin immunogen representative of Salmonella serogroup B O-antigen and characterization of the antibody response.
    Svenson SB, Lindberg AA.
    J Immunol; 1978 May 10; 120(5):1750-7. PubMed ID: 351058
    [Abstract] [Full Text] [Related]

  • 40.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 15.